Oncology

The objective response rate among patients treated at DL2 and DL3 who were evaluable for efficacy was 57%.

The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed real-world safety outcomes for brexu-cel in patients with r/r MCL.

Among 101 patients included in the efficacy analysis, the ORR was 96% and the CR rate was 74.3%.

The director of University of Washington Medicine’s Cancer Vaccine institute discussed results from a phase 1 study presented at ASCO’s 2023 conference.

Review top news and interview highlights from the week ending June 9, 2023.

The most recent data from CARTITUDE-4 were presented at the 2023 ASCO Meeting.

The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed the real-world data she is presenting at EHA’s 2023 congress.

Updated data were presented at the ISCT 2023 Meeting.

The associate professor at Medical College of Wisconsin discussed the rationale for the CARTITUDE-4 study and its latest updates.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The study has enrolled 17 patients as of May 2023 and enrollment is expected to complete by the end of 2024.

New overall survival analysis data on Yescarta from ZUMA-7 were presented at the ASCO 2023 meeting.

The associate professor at University College London also discussed unmet needs that remain in r/r B-ALL and another presentation of interest at ASCO’s 2023 conference.

The professor of medicine and pediatrics at Washington University in St. Louis discussed evaluating afami-cel in the SPEARHEAD-1 trial.

Among 19 patients with r/r B-ALL included in the analysis, all 19 achieved a CR or CRi.

Safety findings were also improved when compared with the previous CARTITUDE-1 study, suggesting the therapy may be better tolerated in earlier lines of therapy.

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed the implications of overall survival data that he presented at ASCO’s 2023 conference.

The study began enrollment in January 2023.

Additionally, promising efficacy signals were reported—namely response rates and disease control rates—in the phase 1 clinical trial (NCT04429087) data that were presented at the 2023 ASCO Annual Meeting.

The professor of medicine and pediatrics at Washington University in St. Louis discussed updated survival data from SPEARHEAD-1.

The associate professor in haemato-oncology at University College London discussed Autolus Therapeutics’ CAR-T, which utilizes a novel fast off-rate CD19 binding domain.

Among 94 patients who were treated with obe-cel in the trial, 76% achieved a CR or CRi.

The autologous CAR T-cell therapy A2B530 is being investigated for solid tumors in the multicenter, first-in-human, phase 1/2 EVEREST-1 study.

Among 70 patients who were able to be evaluated for efficacy at 28 days or more, 91% achieved a complete response or a complete response with incomplete hematological recovery.

Follow-up data were presented from the discontinued phase 3 OVAL study.

There were no DLTs observed among the treated patients.

Maria Pia Morelli, MD, PhD, assistant professor at MD Anderson Cancer Center, discussed the first-in-human study of Sleeping Beauty TCR-T cells.

Among 49 patients who were included in the trial’s primary efficacy analysis set and received dose-level 2, the CR/CRi rate was 18.4%.

Review top news and interview highlights from the week ending June 2, 2023.

The chief scientific officer at Omega Therapeutics discussed positive preclinical data presented at ASCO 2023.